-transparent.png){kind=logo}
Biliary excretion of lithocholate-3-sulfate and ursodeoxycholate 3,7-disulfate is markedly impaired in EHBR. In the present study, the effects of ursodeoxycholate 3,7-disulfate infusion on lithocholate-3-sulfate excretion were studied in EHBR and Sprague-Dawley rats. Although in control rats, ursodeoxycholate 3,7-disulfate infusion had no effect on biliary lithocholate-3-sulfate excretion, in EHBR it enhanced biliary lithocholate-3-sulfate excretion. Although ursodeoxycholate 3,7-disulfate dose-dependently inhibited lithocholate-3-sulfate binding by rat serum albumin and rat liver cytosol, it did not affect the serum clearance of lithocholate-3-sulfate in EHBR in vivo. These findings indicate that in EHBR, in which the major ATP-dependent organic anion transporter is impaired, the excretory pathway for ursodeoxycholate 3,7-disulfate may interact to that for lithocholate-3-sulfate.
H Takikawa, and
N Sano, and
T Ogasawara, and
M Yamanaka
August 2002,
Hepatology research : the official journal of the Japan Society of Hepatology,
H Takikawa, and
N Sano, and
T Ogasawara, and
M Yamanaka
March 1999,
Pancreas,
H Takikawa, and
N Sano, and
T Ogasawara, and
M Yamanaka
September 1995,
The Journal of pharmacology and experimental therapeutics,
H Takikawa, and
N Sano, and
T Ogasawara, and
M Yamanaka
October 2004,
Drug metabolism and pharmacokinetics,
H Takikawa, and
N Sano, and
T Ogasawara, and
M Yamanaka
January 1996,
Biological trace element research,
H Takikawa, and
N Sano, and
T Ogasawara, and
M Yamanaka
January 1995,
Antimicrobial agents and chemotherapy,
H Takikawa, and
N Sano, and
T Ogasawara, and
M Yamanaka
April 2005,
Pharmaceutical research,
H Takikawa, and
N Sano, and
T Ogasawara, and
M Yamanaka
January 2003,
Pharmaceutical research,
H Takikawa, and
N Sano, and
T Ogasawara, and
M Yamanaka
March 1997,
Digestive diseases and sciences,
H Takikawa, and
N Sano, and
T Ogasawara, and
M Yamanaka
February 1973,
The Journal of pharmacology and experimental therapeutics,
